February 13, 2022 /
MS Research Study and Reports
January 20, 2022 04:26 PM Eastern Standard Time
METUCHEN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced its intention to study its proprietary off-the-shelf T cell technology to develop therapeutic solutions for multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific CD8+ cytotoxic T lymphocytes (CTL). Multiple sclerosis is a chronic inflammatory disease of the central nervous system, for which there is currently no definitive cure.
“Recent studies on multiple sclerosis have suggested a probable link between latent infection with EBV and later onset of the inflammation that degrades the myelin sheath and causes multiple sclerosis,” said Neal Flomenberg, M.D., Chairman of Tevogen’s Scientific Advisory Board. “We look to apply our significant expertise in off-the-shelf allogeneic SARS-CoV-2 specific CD8+ cytotoxic T lymphocytes (CTLs) to explore EBV specific CTL therapy as a possible means of addressing the unmet needs of MS patients,” Flomenberg added.
“Anyone that knows someone who has been impacted by this debilitating disease understands the importance of advancing science to develop pathways to alleviate the suffering from MS,” said Tevogen CEO Ryan Saadi, M.D., M.P.H. “I’m hopeful that our disruptive T cell technology will eventually offer accessible immunotherapies to millions suffering from viral infections, cancers and other diseases with high unmet need.”
About Tevogen’s Investigational T Cell Therapy for COVID-19
Tevogen’s investigational T cell therapy for COVID-19, TVGN-489, is currently undergoing proof of concept clinical trial at Jefferson University Hospitals in Philadelphia. Trial details are available at Clinical Trials – Tevogen.
TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product, which detects targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virally infected cells, allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong activity against SARS-CoV-2 targets in preclinical studies.
Click to Subscribe for the MS Beacon eNewsletter and MS educational events
|
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
Categories
Latest Blog Posts
- Nasal MS therapy moves closer to results after final patient dosed
- Caregivers are like human assistive devices, but with feelings
- MS Takes a Toll on Caregivers, Too, Especially on Their Mental Health
- An MS caregiver’s dilemma: Do I stay or do I go?
- Variant tied to severe MS may affect cognition in healthy adults
- Trouble retrieving the right words with MS likely tied to cognition
- AI Reveals Hidden Gray Matter Lesions in Multiple Sclerosis
- 7 Self-Care Tips for Multiple Sclerosis
- MS Exercises for Better Balance and Coordination
- Improving access to NMOSD diagnosis: Multicenter evaluation of the iDOT AQP4 assay
- GLP-1 therapies and cognitive impairment: New data highlights possible “survival paradox”
- New research findings challenge old beliefs about myelin repair in MS
- FDA OKs first human trial of oral MS remyelination therapy PTD802
- Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU (European Union) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
- FDA clears CTA313 (Car-T Cellular Therapy) trial for progressive MS, autoimmune disease
- Multiple Sclerosis or Lupus: Can You Have Both?
- What to Know About the Link Between Multiple Sclerosis and Psoriatic Arthritis
- Is an MS Flare-Up the Same as a Relapse?
- Going Gluten-Free for MS? Here Are 5 Easy Recipes
- Blood Proteins Identified That Predict Multiple Sclerosis Early
